Frank Strelow
Research Subjects
Frank Strelow has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Do Minh Thai
Centre for Epidemiology & Health Research Berlin, Invalidenstr. 115, 10115 Berlin, Germany
2 shared publications - Hermann Pg Schneider
University Muenster, Dept. Obstetrics and Gynecology, Von-Esmarch-Strasse 56, 48149 Muenster, Germany
2 shared publications - Lothar A. J. Heinemann
Centre for Epidemiology & Health Research Berlin, Invalidenstr. 115, 10115 Berlin, Germany
2 shared publications - Alexander Ruebig
Berlex Canada Inc., 334 Avenue Avro, Pointe-Claire (Québec) H9R 5W5, Canada
1 shared publication - Jörg Schnitker
Institut für angewandte Statistik Dr. Jörg Schnitker GmbH, 33602 Bielefeld, Germany
1 shared publication - Klaas Heinemann
Center for Epidemiology & Health Research Berlin, Bayer Schering Pharmaceuticals, Berlin, Germany
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 2 September 2004
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 2 (1) , 1-45
The Menopause Rating Scale (MRS) scale: A methodological review
Background: This paper compiles data from different sources to get a first comprehensive picture of psychometric and other methodological characteristics of the Menopause Rating Scale (MRS) scale. The scale was designed and standardized as a self-administered scale to (a) to assess symptoms/complaints of aging women under different conditions, (b) to evaluate the severity of symptoms over time, and (c) to measure changes pre- and postmenopause replacement therapy. The scale became widespread used (available in 10 languages). Method: A large multinational survey (9 countries in 4 continents) from 2001/ 2002 is the basis for in depth analyses on reliability and validity of the MRS. Additional small convenience samples were used to get first impressions about test-retest reliability. The data were centrally analyzed. Data from a postmarketing HRT study were used to estimate discriminative validity. Results: Reliability measures (consistency and test-retest stability) were found to be good across countries, although the sample size for test-retest reliability was small. Validity: The internal structure of the MRS across countries was astonishingly similar to conclude that the scale really measures the same phenomenon in symptomatic women. The sub-scores and total score correlations were high (0.7–0.9) but lower among the sub-scales (0.5–0.7). This however suggests that the subscales are not fully independent. Norm values from different populations were presented showing that a direct comparison between Europe and North America is possible, but caution recommended with comparisons of data from Latin America and Indonesia. But this will not affect intra-individual comparisons within clinical trials. The comparison with the Kupperman Index showed sufficiently good correlations, illustrating an adept criterion-oriented validity. The same is true for the comparison with the generic quality-of-life scale SF-36 where also a sufficiently close association has been shown. Conclusion: The currently available methodological evidence points towards a high quality of the MRS scale to measure and to compare HRQoL of aging women in different regions and over time, it suggests a high reliability and high validity as far as the process of construct validation could be completed yet.
- 2 September 2004
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 2 (1) , 1-45
Top Cited PapersOpen AccessThe Menopause Rating Scale (MRS) scale: A methodological review
Background: This paper compiles data from different sources to get a first comprehensive picture of psychometric and other methodological characteristics of the Menopause Rating Scale (MRS) scale. The scale was designed and standardized as a self-administered scale to (a) to assess symptoms/complaints of aging women under different conditions, (b) to evaluate the severity of symptoms over time, and (c) to measure changes pre- and postmenopause replacement therapy. The scale became widespread used (available in 10 languages). Method: A large multinational survey (9 countries in 4 continents) from 2001/ 2002 is the basis for in depth analyses on reliability and validity of the MRS. Additional small convenience samples were used to get first impressions about test-retest reliability. The data were centrally analyzed. Data from a postmarketing HRT study were used to estimate discriminative validity. Results: Reliability measures (consistency and test-retest stability) were found to be good across countries, although the sample size for test-retest reliability was small. Validity: The internal structure of the MRS across countries was astonishingly similar to conclude that the scale really measures the same phenomenon in symptomatic women. The sub-scores and total score correlations were high (0.7–0.9) but lower among the sub-scales (0.5–0.7). This however suggests that the subscales are not fully independent. Norm values from different populations were presented showing that a direct comparison between Europe and North America is possible, but caution recommended with comparisons of data from Latin America and Indonesia. But this will not affect intra-individual comparisons within clinical trials. The comparison with the Kupperman Index showed sufficiently good correlations, illustrating an adept criterion-oriented validity. The same is true for the comparison with the generic quality-of-life scale SF-36 where also a sufficiently close association has been shown. Conclusion: The currently available methodological evidence points towards a high quality of the MRS scale to measure and to compare HRQoL of aging women in different regions and over time, it suggests a high reliability and high validity as far as the process of construct validation could be completed yet.
- Open Access
- 1 January 2004
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 2 (1) , 1-67
The Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A validation study
The Menopause Rating Scale is a health-related Quality of Life scale developed in the early 1990s and step-by-step validated since then. No methodologically detailed work on the utility of the scale to assess health-related changes after treatment was published before.
- 1 January 2004
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 2 (1) , 1-67
Open AccessThe Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A validation study
The Menopause Rating Scale is a health-related Quality of Life scale developed in the early 1990s and step-by-step validated since then. No methodologically detailed work on the utility of the scale to assess health-related changes after treatment was published before.